donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
NVO Novo-Nordisk A/S
111.640
+0.210+0.19%
Post Mkt Price
111.64000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Investing cash flow
Cash flow from continuing investing activities
45.22% -1.91B -40.87% -31.61B -59.71% -20.6B 23.55% -4.64B
Net PPE purchase and sale
-8.42% -1.52B -8.89% -6.34B -35.34% -2.05B 15.95% -1.18B
Net intangibles purchase and sale
-168.04% -260M 93.54% -1.05B 97.67% -265M 89.05% -513M
Net business purchase and sale
-- -- -4564.03% -18.28B -- -18.28B -- 0
Net investment purchase and sale
93.61% -127M -49608.33% -5.94B -700% -6M -- -2.95B
Cash from discontinued investing activities
Investing cash flow
45.22% -1.91B -40.87% -31.61B -59.71% -20.6B 23.55% -4.64B
Financing cash flow
Cash flow from continuing financing activities
-32.19% -19.14B 20.94% -25.49B 1363.61% 4.55B -9.7% -11.73B
Net issuance payments of debt
-388.54% -1.71B 226.94% 15.47B 127.57% 12.06B -25% -175M
Net common stock issuance
-51.25% -4.48B -15.38% -19.45B -32.72% -7.51B -18.47% -3.54B
Cash dividends paid
-16.27% -15.69B -6.94% -21.52B -- 0 -5.96% -8.02B
Net other financing activities
17.52% 2.74B -- -- -- -- -- --
Cash from discontinued financing activities
Financing cash flow
-32.19% -19.14B 20.94% -25.49B 1363.61% 4.55B -9.7% -11.73B
Net cash flow
Beginning cash position
-12.33% 10.72B -20.67% 12.23B 15.81% 29.49B -2.51% 24.23B
Current changes in cash
137.96% 2.54B 23.12% -2.1B -45.71% -19.07B 586.38% 5.14B
Effect of exchange rate changes
-135.71% -55M 229.61% 591M 298.68% 300M 190.37% 122M
End cash Position
132.58% 13.21B -12.33% 10.72B -12.33% 10.72B 15.81% 29.49B
Free cash flow
123.51% 21.81B 59.41% 47.62B 58.13% -5.33B 73.55% 19.82B
Investing cash flow
Cash flow from continuing investing activities
45.22% -1.91B -40.87% -31.61B -59.71% -20.6B 23.55% -4.64B
Net PPE purchase and sale
-8.42% -1.52B -8.89% -6.34B -35.34% -2.05B 15.95% -1.18B
Net intangibles purchase and sale
-168.04% -260M 93.54% -1.05B 97.67% -265M 89.05% -513M
Net business purchase and sale
-- -- -4564.03% -18.28B -- -18.28B -- 0
Net investment purchase and sale
93.61% -127M -49608.33% -5.94B -700% -6M -- -2.95B
Cash from discontinued investing activities
Investing cash flow
45.22% -1.91B -40.87% -31.61B -59.71% -20.6B 23.55% -4.64B
Financing cash flow
Cash flow from continuing financing activities
-32.19% -19.14B 20.94% -25.49B 1363.61% 4.55B -9.7% -11.73B
Net issuance payments of debt
-388.54% -1.71B 226.94% 15.47B 127.57% 12.06B -25% -175M
Net common stock issuance
-51.25% -4.48B -15.38% -19.45B -32.72% -7.51B -18.47% -3.54B
Cash dividends paid
-16.27% -15.69B -6.94% -21.52B -- 0 -5.96% -8.02B
Net other financing activities
17.52% 2.74B -- -- -- -- -- --
Cash from discontinued financing activities
Financing cash flow
-32.19% -19.14B 20.94% -25.49B 1363.61% 4.55B -9.7% -11.73B
Net cash flow
Beginning cash position
-12.33% 10.72B -20.67% 12.23B 15.81% 29.49B -2.51% 24.23B
Current changes in cash
137.96% 2.54B 23.12% -2.1B -45.71% -19.07B 586.38% 5.14B
Effect of exchange rate changes
-135.71% -55M 229.61% 591M 298.68% 300M 190.37% 122M
End cash Position
132.58% 13.21B -12.33% 10.72B -12.33% 10.72B 15.81% 29.49B
Free cash flow
123.51% 21.81B 59.41% 47.62B 58.13% -5.33B 73.55% 19.82B
Currency Unit
DKKDKKDKKDKK
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
CEO: Jorgensen, Lars Fruergaard
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...